Pablo Umaña

Enhancing endogenous and synthetic immunity with engineered antibody-fusion proteins for cancer immunotherapy

A new generation of engineered fusion proteins is currently being developed to enhance endogenous and synthetic immunity approaches for cancer immunotherapy The talk with cover both a PD-1-cis-targeted IL-2 variant used to differentiate antigen-specific, stem-like T cells into better effectors, and also the combination of tumor-targeted costimulatory receptor agonists with T-cell engaging bispecific antibodies as an off-the-shelf approach for enhanced T cell redirection. Both of these approaches are currently being tested in first-in-class clinical trials.